The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase II multicenter study of the efficacy and safety of sunitinib given on an individualized schedule as first-line therapy for metastatic renal cell cancer.
Georg A. Bjarnason
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Research Funding - Pfizer
Naveen S. Basappa
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Jennifer J. Knox
Research Funding - Pfizer
Christian K. Kollmannsberger
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
M. Neil Neil Reaume
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Pawel Zalewski
No relevant relationships to disclose
Robyn Jane Macfarlane
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Mary J. MacKenzie
Honoraria - Pfizer
Sebastien J. Hotte
No relevant relationships to disclose
Daniel Yick Chin Heng
Consultant or Advisory Role - Pfizer
Denis Soulieres
Consultant or Advisory Role - Pfizer
Honoraria - Pfizer
Jessie Miller
No relevant relationships to disclose